UNSPSC 51372001: Desomorphine

This classification denotes an opioid receptor agonist with the molecular formula C17H21NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7OP86J5E33, chemically known as morphinan-3-ol, 4,5-epoxy-17-methyl-, (5.alpha.)- but generally known as desomorphine, which bears US NIH Compound Identifier 521115. European Medicines Agency schedules Desomorphine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07004MIG. The term DESOMORPHINE is an International Non-Proprietary Name.

UNSPSC 51372001 Desomorphine, a Commodity code, does not align with the state and local procurement activity recently tagged to it. The three most recent solicitations under this code involve naloxone procurement, direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals and over-the-counter products — none of which concern desomorphine, an opioid precursor with no legitimate commercial medical use in the United States. The mismatch suggests either a data classification error in the source records or misapplication of the code by issuing bodies unfamiliar with UNSPSC taxonomy at the commodity tier.

State and local health agencies, cooperative purchasing alliances, and state health and human services departments are actively procuring naloxone, pharmaceutical distribution arrangements, and generic medications through competitive bidding and request-for-proposal processes, but these activities are not properly reflected under the desomorphine commodity code. Seminole County, Florida issued an IFB on June 30, 2026, for naloxone and safe drug deactivation systems with a July 26, 2023 response deadline; the Texas Health and Human Services Commission posted an RFI on April 3, 2026, regarding direct-to-manufacturer prescription fulfillment; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) released an RFP on January 20, 2026, for generic pharmaceuticals and OTC products with a March 26, 2026 deadline. The code shows little activity aligned with its stated scope, and pursuit decisions should be informed by confirming whether the correct UNSPSC code applies to the pharmaceutical and public health procurement opportunities actually being sought.